Private practice with Dr Seth BilazarianView all posts »
Why doesn't the FDA trust us with dabigatran dosing?May 20, 2011 11:00 EDT
The FDA sends out a clear message relating to its recent ruling on dabigatran dosing: clinicians and patients can't be trusted to get the dosing of dabigatran right. What other rationale can there be for this decision?
Beasley BN, Unger EF, Temple R. Anticoagulant options--Why the FDA approved a higher but not a lower dose of dabigatran. New Engl J Med 2011; 364:1788-1790. Available here.